# BRISTOL-MYERS SQUIBB COMPANY (BMY) · Edgar & Edgarette company card

> Bristol-Myers Squibb Company (BMY) saw revenue fall 0.2% in FY2025 to $48.2 billion, equity 20.5% of assets, and dividend per share up 18 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 14272 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BMY) · [JSON](https://www.pops4.com/boards/company/BMY.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $48.2B |
| Revenue growth, 1 year | -0.2% |
| Revenue growth per year | 1.0% |
| Operating margin | — |
| Net margin | 14.6% |
| Operating cash flow | $14.2B |
| Capital spending | $1.3B |
| Free cash flow | $12.8B |
| Cash | $10.2B |
| Long-term debt | $44.8B |
| Total assets | $90.0B |
| Total equity | $18.5B |
| Equity ÷ assets | 20.5% |
| Return on equity | 38.2% |
| Dividend per share | $2.49 |
| Dividend years rising | 18 |

## Readings, computed from those figures

- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.68 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow now · steady, with strong cash arriving today

## Edgarette's reading

Exposure: revenue $48.2B (FY2025), total debt $44.8B. Experience: revenue down 0.2% on the year, up 1.0% a year over 4 years. Soundness: equity 20.5% of assets, return on equity 38.2%, payout 71.5% of profit, dividend per share up 18 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $43.5B and $50.6B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $40.7B to $53.8B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): growth -0.2% against 13.7%.

Range logged 2026-09-26, receipt 1b40a0dcc80e5f7e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/0000014272-26-000024-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/0000014272-26-000022-index.htm)
- 10-Q · filed 2026-07-30 · [filing](https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/0000014272-26-000020-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/0000014272-26-000018-index.htm)
- 8-K · filed 2026-05-08 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/14272/000114036126020036/0001140361-26-020036-index.htm)
- 10-Q · filed 2026-04-30 · [filing](https://www.sec.gov/Archives/edgar/data/14272/000001427226000010/0000014272-26-000010-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000014272.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=14272

## Cite

POPS4, Edgar & Edgarette: BRISTOL-MYERS SQUIBB COMPANY (BMY) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/BMY. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.